Laboratorios Farmaceuticos ROVI (ROVI.MC) Stock Price
Laboratorios Farmaceuticos ROVI Price
Revenue has compounded at 12.6% per year over the past 19 years to 743.48 M EUR. Earnings per share have grown at 19.0% per year over the last 19 years. Laboratorios Farmaceuticos ROVI's net margin stands at 18.9%, down from 23.6% several years earlier. Laboratorios Farmaceuticos ROVI currently offers a dividend yield of about 1.58%. The payout ratio is around 34% of earnings. The dividend has grown at 15.7% per year over the past 17 years. Analysts set a median price target of 85.07 EUR, implying 43.3% above the current price. Of 16 analysts, 13 rate the stock a buy — an overall Buy consensus.
Laboratorios Farmaceuticos ROVI stock price
Laboratorios Farmaceuticos ROVI business model & stock analysis
Frequently asked questions about Laboratorios Farmaceuticos ROVI
The business model of Laboratorios Farmaceuticos ROVI SA focuses on pharmaceutical research, development, manufacturing, and commercialization. The company operates in the specialty pharmaceuticals industry and specializes in the production of injectable pharmaceuticals and various other drugs. Laboratorios Farmaceuticos ROVI SA collaborates with international partners for the licensing and distribution of its products. With a strong emphasis on innovation and quality, the company aims to provide healthcare solutions through its unique product portfolio. Laboratorios Farmaceuticos ROVI SA actively pursues partnerships and collaborations to expand its market reach and continuously improve its product pipeline.
Laboratorios Farmaceuticos ROVI SA is primarily active in the pharmaceutical industry.
The main competitors of Laboratorios Farmaceuticos ROVI SA in the market include pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Sanofi.
Laboratorios Farmaceuticos ROVI SA is a renowned pharmaceutical company with an impressive history and background. Established in 1946, ROVI SA has consistently focused on developing and manufacturing innovative healthcare solutions. With its headquarters in Madrid, Spain, the company operates in various therapeutic areas, including Special Focused Medicines, Biosimilars, and Active Pharmaceutical Ingredients (APIs). ROVI SA has a strong commitment to research and development, striving to improve patients' quality of life through cutting-edge treatments. Over the years, the company has gained recognition and trust from healthcare practitioners and patients alike, solidifying its position as a prominent player in the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA has achieved several significant milestones throughout its history. One noteworthy achievement is its development of innovative pharmaceutical products, including advanced drug delivery systems and therapeutic solutions. The company has also gained recognition for its expertise in biopharmaceutical manufacturing and has successfully established numerous strategic partnerships globally. Additionally, Laboratorios Farmaceuticos ROVI SA has demonstrated consistent growth and profitability, expanding its market presence and enhancing shareholder value. These achievements reflect the company's commitment to delivering high-quality healthcare solutions and driving advancements within the pharmaceutical industry.
Laboratorios Farmaceuticos ROVI SA is primarily present in Spain, where the company is based. Additionally, ROVI has a global presence, with its products and services being available in several other countries and regions around the world. These include various European countries such as Germany, France, Italy, Portugal, and the United Kingdom. Furthermore, ROVI has a significant presence in the Americas, including Mexico, Brazil, and Colombia. With its international reach, Laboratorios Farmaceuticos ROVI SA has established a strong presence in both European and American markets, catering to a wide range of customers and expanding its global footprint.
Laboratorios Farmaceuticos ROVI SA represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy centered on the development and manufacturing of innovative medicines and healthcare products, ROVI prioritizes patient well-being and strives for scientific advancement. The company's commitment to research and development, along with its focus on partnerships with healthcare professionals and organizations, enables ROVI to provide innovative solutions that improve patients' lives. By embracing a culture of responsibility, transparency, and ethical practices, Laboratorios Farmaceuticos ROVI SA aims to contribute to global healthcare and deliver value to its stakeholders.
Analysts currently set an average price target of 84.26 EUR for the Laboratorios Farmaceuticos ROVI stock (median: 85.07 EUR), implying +42.0 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Laboratorios Farmaceuticos ROVI stock: 13 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Laboratorios Farmaceuticos ROVI to generate revenue of 773.24 M EUR and earnings per share of 2.72 EUR.
The Laboratorios Farmaceuticos ROVI share (ROVI.MC) is listed on 9 stock exchanges, including: London (0ILL.L), SIX (Zürich) (41L.SW), Frankfurt (41L.F), München (41L.MU), Düsseldorf (41L.DU), Madrid (ROVI.MC).
Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the development and production of biotechnological drugs, vaccines, and generics. The company was founded in Spain in 1946 and has since built an impressive track record. Today, ROVI is a global player with customers in over 80 countries worldwide. ROVI operates in three business segments: Innovation, Generics, and Specialties. In the Innovation segment, the company focuses on biotechnological drugs and vaccines, with a particular emphasis on tissue repair, kidney and liver diseases, and immuno-oncology. The pipeline of Innovation includes a variety of innovative drugs in various stages of clinical development. A significant milestone for the company was the successful approval of Doria®, an inactivated SARS-CoV-2 vaccine for individuals aged 18 years and older. In the Generics segment, ROVI focuses on high-quality generics for various diseases. The company has strong partnerships worldwide, giving it access to a broad network of producers and suppliers. ROVI is an important supplier to the public health sector in many countries. The Specialties segment comprises different products, such as contrast agents for medical imaging, wound care, and non-surgical wrinkle treatment. ROVI's product range includes a variety of drugs and vaccines for different diseases and applications. Some of the most well-known products are Envarsus® for preventing transplant rejection in kidney or liver transplantations, Bemiparin as an anticoagulant for the prevention and treatment of thrombosis, and Hepacare® for the treatment of Hepatitis C, used in countries like Pakistan to reduce the spread of the disease. To meet the growing needs of the healthcare market, ROVI has invested in research and development. The company has expanded its research and development pipeline and works on developing innovative drugs and products. ROVI is also known for investing in partnerships. The company collaborates closely with other bio-pharmaceutical companies and research institutes to develop new drugs. These partnerships also open up new markets and provide access to new technologies. In summary, ROVI SA has been active as a strategic and influential company in the biopharmaceutical world. Investments in research and development, innovation, and partnerships have contributed to ROVI's recognition in the industry. With a wide network of producers and suppliers worldwide and customers in over 80 countries, ROVI is globally present and has established a strong position in the public health sector.
The expected revenue of Laboratorios Farmaceuticos ROVI is 773.24 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Laboratorios Farmaceuticos ROVI is 139.19 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Laboratorios Farmaceuticos ROVI is currently 21.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Laboratorios Farmaceuticos ROVI stock.
The price-to-sales ratio (P/S) of Laboratorios Farmaceuticos ROVI is currently 3.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Laboratorios Farmaceuticos ROVI stock.
The Eulerpool Quality Score for Laboratorios Farmaceuticos ROVI is 6/10.
The ISIN of Laboratorios Farmaceuticos ROVI is ES0157261019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Laboratorios Farmaceuticos ROVI is A0M0GQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Laboratorios Farmaceuticos ROVI is ROVI.MC. The ticker symbol is used to trade Laboratorios Farmaceuticos ROVI shares on the stock exchange.
Laboratorios Farmaceuticos ROVI stock
Laboratorios Farmaceuticos ROVI Peer Group
Laboratorios Farmaceuticos ROVI Ticker
Laboratorios Farmaceuticos ROVI FIGI
All fundamentals and in-depth analysis of Laboratorios Farmaceuticos ROVI
Our stock analysis for Laboratorios Farmaceuticos ROVI stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.